Ambu is intensifying its efforts to create the next generation of its duodenoscopes. A number of competitors are circling, and an upcoming tender is a good opportunity for income. CEO Juan Jose Gonzalez calls the new duodenoscope the biggest earner of the future.
BY ULRICH QUISTGAARD, TRANSLATED BY CATHERINE BRETT
As CEO of Ambu, Juan Jose Gonzalez has looked forward to announcements of tenders for single-use endoscopes in the US. However, competitors are homing in on Ambu's key business area.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.